AN2 Therapeutics Ownership | Who Owns AN2 Therapeutics?

AN2 Therapeutics Ownership Summary

AN2 Therapeutics is owned by 27.30% institutional investors, 25.46% insiders, and 47.24% retail investors. Citadel advisors is the largest institutional shareholder, holding 5.22% of ANTX shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.68% of its assets in AN2 Therapeutics shares.

ANTX Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	AN2 Therapeutics	27.30%	25.46%	47.24%
Sector	Healthcare Stocks	42.50%	10.81%	46.69%
Industry	Biotech Stocks	45.24%	10.75%	44.01%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Citadel advisors	1.55M	5.22%	$3.34M
Almitas capital	1.43M	4.73%	$1.81M
Vanguard group	1.08M	3.58%	$1.37M
Pfizer	715.29K	2.37%	$908.42K
Peapod lane capital	589.22K	1.95%	$748.32K
Stonepine capital management	563.91K	1.87%	$716.17K
Bank of nova scotia	459.19K	1.52%	$583.18K
Landscape capital management	456.46K	1.51%	$579.71K
Bank of montreal /can/	422.08K	1.40%	$536.04K
Renaissance	385.60K	1.28%	$489.71K

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Peapod lane capital	589.22K	0.67%	$748.32K
Stonepine capital management	563.91K	0.58%	$716.17K
Almitas capital	1.43M	0.42%	$1.81M
Pfizer	715.29K	0.21%	$908.42K
Rangeley capital	65.00K	0.07%	$82.55K
Landscape capital management	456.46K	0.04%	$579.71K
Act advisors, llc.	13.20K	0.01%	$16.76K
Highline wealth partners	5.00K	0.00%	$6.35K
Bridgeway capital management	59.90K	0.00%	$76.07K
Xtx topco	18.54K	0.00%	$23.55K

Top Buyers

Holder	Shares	% Assets	Change
Goldman sachs group	224.19K	0.00%	195.81K
Squarepoint ops	64.27K	0.00%	54.20K
Vanguard group	1.08M	-	44.12K
Captrust financial advisors	40.00K	0.00%	30.00K
Stonepine capital management	563.91K	0.58%	19.42K

Top Sellers

Holder	Shares	% Assets	Change
Bml capital management	-	-	-5.75M
Octagon capital advisors lp	-	-	-3.22M
Frazier life sciences management	-	-	-2.09M
Ra capital management	-	-	-2.00M
Tcg crossover management	-	-	-1.56M

New Positions

Holder	Shares	% Assets	Change	Value
Act advisors, llc.	13.20K	0.01%	13.20K	$16.76K
Royal bank of canada	2.81K	-	2.81K	$6.00K
Fmr	1.00K	-	1.00K	$1.27K

Sold Out

Holder	Change
Jpmorgan chase	-49.00
Wells fargo & company/mn	-128.00
Coldstream capital management	-783.00
California state teachers retirement system	-9.25K
Clear street markets	-10.00K

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Sep 30, 2025	34	-	8,236,317	1.76%	27	3.79%	9	-40.00%	11	120.00%
Jun 30, 2025	36	-	8,284,557	-36.41%	27	1.46%	17	30.77%	5	-54.55%
Mar 31, 2025	37	-	14,340,830	-1.29%	47	2.01%	13	-45.83%	11	57.14%
Dec 31, 2024	37	19.35%	14,528,930	7.52%	48	2.37%	24	50.00%	7	-
Sep 30, 2024	31	-31.11%	13,513,224	-30.40%	45	1.06%	16	-20.00%	7	-46.15%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard Total Stock Mkt Idx Inv	733.39K	2.68%	-16.03K
Vanguard Institutional Extnd Mkt Idx Tr	179.94K	0.66%	-81.99K
Fidelity Extended Market Index	117.68K	0.43%	-968.00
Bridgeway Ultra-Small Company Market	59.00K	0.22%	-
iShares Micro-Cap ETF	51.33K	0.19%	-
Fidelity Total Market Index	48.79K	0.18%	-104.00
BlackRock Extended Equity Market K	33.77K	0.11%	-14.00
Bridgeway Ultra-Small Company	33.20K	0.11%	33.20K
Fidelity Series Total Market Index	30.27K	0.11%	-
Extended Equity Market Fund K	32.76K	0.11%	-654.00

Recent Insider Transactions

Date	Name	Role	Activity	Value
Nov 04, 2025	Eizen Joshua M	See Remarks	Sell	$3.21K
Nov 04, 2025	Prior Stephen David	Chief Strategy Officer	Sell	$872.10
May 28, 2025	Leonard Braden Michael	-	Sell	$218.00K
Jun 02, 2025	Easom Eric	Chief Executive Officer	Buy	$10.66K
May 28, 2025	Leonard Braden Michael	-	Sell	$2.32M

Insider Transactions Trends

Date	Buy	Sell
2025 Q4	-	2
2025 Q3	-	-
2025 Q2	2	5
2025 Q1	-	4
2024 Q4	18	-

ANTX Ownership FAQ

Who Owns AN2 Therapeutics?

AN2 Therapeutics shareholders are primarily institutional investors at 27.30%, followed by 25.46% insiders and 47.24% retail investors. The average institutional ownership in AN2 Therapeutics's industry, Biotech Stocks , is 45.24%, which AN2 Therapeutics falls below.

Who owns the most shares of AN2 Therapeutics?

AN2 Therapeutics’s largest shareholders are Citadel advisors (1.55M shares, 5.22%), Almitas capital (1.43M shares, 4.73%), and Vanguard group (1.08M shares, 3.58%). Together, they hold 13.53% of AN2 Therapeutics’s total shares outstanding.

Does Blackrock own AN2 Therapeutics?

BlackRock is not among the top 10 institutional shareholders of AN2 Therapeutics.

Who is AN2 Therapeutics’s biggest shareholder by percentage of total assets invested?

Peapod lane capital is AN2 Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.67% of its assets in 589.22K AN2 Therapeutics shares, valued at 748.32K$.

Who is the top mutual fund holder of AN2 Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of AN2 Therapeutics shares, with 2.68% of its total shares outstanding invested in 733.39K AN2 Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools